Clinical outcomes and safety endpoints of any heparin use versus no heparin use stratified by ASPECTS score
| ASPECTS 0–7 | ASPECTS 8–10 | |||||
| Heparin (+) n=24 % | Heparin (−) n=56 % | p Value | Heparin (+) n=28 % | Heparin (−) n=53 % | p Value | |
| 90-day modified Rankin score | 0.38 | 0.78 | ||||
| 0 | 4.3 | 0 | 23.1 | 17.0 | ||
| 1 | 13.0 | 5.6 | 15.4 | 13.2 | ||
| 2 | 17.4 | 11.1 | 11.5 | 5.7 | ||
| 3 | 4.3 | 16.6 | 7.7 | 17.0 | ||
| 4 | 17.4 | 24.1 | 15.4 | 24.5 | ||
| 5 | 4.3 | 7.4 | 3.8 | 3.8 | ||
| 6 | 39.1 | 35.2 | 23.1 | 18.9 | ||
| 90-day good outcome (mRS 0–2) (95% CI) | 34.8 (16.4 to 57.3) | 16.7% (7.9 to 29.3) | 0.13 | 50.0 (29.9 to 70.1) | 35.8 (23.1 to 50.2) | 0.33 |
| 90-day mortality (95% CI) | 37.5 (18.8 to 59.4) | 33.9 (21.8 to 47.8) | 0.8 | 21.4 (8.3 to 41.0) | 18.9 (9.4 to 32.05) | 0.78 |
| Symptomatic ICH (95% CI) | 16.7 (4.7 to 37.4) | 7.1 (2.0 to 17.3) | 0.23 | 10.7 (2.3 to 28.2) | 1.9 (0.0 to 10.1) | 0.12 |
ICH, intracranial hemorrhage.